Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease
Open Access
- 1 September 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 3 (9) , 1253-1256
Abstract
Erdheim-Chester disease (ECD) is an uncommon histiocytic disorder that is considered a hematologic cancer.1 Because of the rarity of the disease, there are limited data on treatment options and their efficacy. Historically, interferon alfa has been used with variable efficacy, albeit at the cost of adverse effects.2 This limitation has led to the use of other agents in an attempt to find more efficacious and less toxic therapies. Cladribine (2-chloro-2′-deoxyadenosine) is an antimetabolite approved by the US Food and Drug Administration for the treatment of hairy cell leukemia. It has also been shown to have activity in other lymphoid cancers (chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and certain low-grade lymphomas), as well as Langerhans cell histiocytosis. Increasing numbers of case reports demonstrate activity of cladribine in the treatment of ECD.3-10 However, contemporary trial or prospective data are lacking to help discern the response rate and outcomes with this agent. In this study, our objective was to assess the efficacy of cladribine in the treatment of ECD.Keywords
This publication has 15 references indexed in Scilit:
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of langerhans cell histiocytosisVojnosanitetski Pregled, 2016
- Erdheim-Chester disease presenting as periodontal disease: Experience of treatment with cladribine, interferon-a, local radiotherapy and anakinraActa Oncologica, 2015
- Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case seriesBMC Medicine, 2014
- Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseBlood, 2014
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012
- CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patientsBlood, 2011
- [Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide].2011
- Erdheim-Chester disease: Two cases of orbital involvementEye, 2000
- Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.Journal of Clinical Oncology, 1998